David Mingdar Wu, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endophthalmitis | 2 | 2022 | 262 | 1.360 |
Why?
|
| Eye Infections, Bacterial | 2 | 2022 | 235 | 1.340 |
Why?
|
| Cataract Extraction | 2 | 2022 | 481 | 1.210 |
Why?
|
| Retinitis Pigmentosa | 3 | 2021 | 386 | 1.020 |
Why?
|
| Retinal Vessels | 12 | 2021 | 772 | 1.000 |
Why?
|
| Vitrectomy | 6 | 2022 | 365 | 0.980 |
Why?
|
| Cataract | 2 | 2022 | 834 | 0.920 |
Why?
|
| Fluorescein Angiography | 8 | 2021 | 940 | 0.740 |
Why?
|
| Visual Acuity | 13 | 2021 | 2530 | 0.730 |
Why?
|
| Retinal Pigment Epithelium | 3 | 2022 | 302 | 0.690 |
Why?
|
| Retinal Perforations | 3 | 2019 | 131 | 0.690 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2022 | 341 | 0.680 |
Why?
|
| Subretinal Fluid | 1 | 2019 | 24 | 0.670 |
Why?
|
| Retinal Hemorrhage | 1 | 2018 | 96 | 0.630 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 377 | 0.620 |
Why?
|
| Macular Degeneration | 2 | 2022 | 980 | 0.610 |
Why?
|
| Polyps | 1 | 2018 | 189 | 0.590 |
Why?
|
| Retinal Neoplasms | 1 | 2019 | 144 | 0.580 |
Why?
|
| Choroid | 1 | 2018 | 322 | 0.570 |
Why?
|
| Diabetic Retinopathy | 6 | 2021 | 1210 | 0.530 |
Why?
|
| Pericytes | 5 | 2006 | 292 | 0.530 |
Why?
|
| Choroidal Neovascularization | 1 | 2018 | 343 | 0.520 |
Why?
|
| Tomography, Optical Coherence | 10 | 2021 | 2657 | 0.470 |
Why?
|
| Propionibacterium acnes | 2 | 2022 | 66 | 0.420 |
Why?
|
| Intravitreal Injections | 4 | 2022 | 344 | 0.410 |
Why?
|
| Retinal Cone Photoreceptor Cells | 4 | 2021 | 177 | 0.410 |
Why?
|
| Vision Disorders | 1 | 2019 | 1058 | 0.400 |
Why?
|
| Retinal Detachment | 3 | 2020 | 411 | 0.380 |
Why?
|
| Ophthalmology | 1 | 2017 | 508 | 0.370 |
Why?
|
| Scleral Buckling | 2 | 2020 | 84 | 0.320 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2022 | 2038 | 0.290 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 655 | 0.290 |
Why?
|
| Eye Proteins | 1 | 2009 | 646 | 0.270 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2009 | 372 | 0.270 |
Why?
|
| Dependovirus | 2 | 2021 | 706 | 0.250 |
Why?
|
| Potassium Channels | 3 | 2006 | 563 | 0.230 |
Why?
|
| Vision Tests | 1 | 2023 | 167 | 0.220 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 3523 | 0.220 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2022 | 52 | 0.210 |
Why?
|
| Contrast Sensitivity | 1 | 2023 | 244 | 0.210 |
Why?
|
| Parasympathetic Nervous System | 1 | 2003 | 141 | 0.210 |
Why?
|
| Goldfish | 1 | 2001 | 65 | 0.200 |
Why?
|
| Bronchial Neoplasms | 1 | 2002 | 112 | 0.200 |
Why?
|
| Color Vision | 1 | 2021 | 21 | 0.190 |
Why?
|
| Vitreous Hemorrhage | 1 | 2021 | 48 | 0.190 |
Why?
|
| Retinal Neovascularization | 2 | 2021 | 244 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2022 | 3508 | 0.190 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2022 | 350 | 0.180 |
Why?
|
| Membrane Potentials | 6 | 2011 | 1137 | 0.180 |
Why?
|
| Thioredoxins | 1 | 2021 | 213 | 0.180 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2021 | 964 | 0.170 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2020 | 117 | 0.170 |
Why?
|
| Endotamponade | 1 | 2019 | 35 | 0.170 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 664 | 0.170 |
Why?
|
| Myopia | 1 | 2021 | 254 | 0.160 |
Why?
|
| Adenosine Triphosphate | 2 | 2003 | 2025 | 0.160 |
Why?
|
| Epiretinal Membrane | 1 | 2019 | 68 | 0.160 |
Why?
|
| Retina | 7 | 2023 | 2616 | 0.160 |
Why?
|
| Laser Coagulation | 1 | 2020 | 326 | 0.160 |
Why?
|
| Patch-Clamp Techniques | 7 | 2011 | 964 | 0.160 |
Why?
|
| Blood Cell Count | 1 | 2019 | 403 | 0.150 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 1866 | 0.150 |
Why?
|
| Indocyanine Green | 1 | 2018 | 239 | 0.150 |
Why?
|
| Retinal Degeneration | 1 | 2021 | 415 | 0.140 |
Why?
|
| Capillaries | 4 | 2011 | 773 | 0.140 |
Why?
|
| Optic Disk | 1 | 2020 | 400 | 0.140 |
Why?
|
| Coloring Agents | 1 | 2018 | 566 | 0.140 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 913 | 0.130 |
Why?
|
| Leukostasis | 1 | 2015 | 22 | 0.130 |
Why?
|
| Oxotremorine | 2 | 2006 | 10 | 0.130 |
Why?
|
| Corneal Diseases | 1 | 2022 | 636 | 0.130 |
Why?
|
| Microcirculation | 3 | 2011 | 1286 | 0.130 |
Why?
|
| Angiotensin II | 2 | 2011 | 881 | 0.130 |
Why?
|
| Rats, Long-Evans | 4 | 2011 | 387 | 0.130 |
Why?
|
| Fibrinolysin | 1 | 2014 | 131 | 0.120 |
Why?
|
| Dopamine | 1 | 2001 | 1591 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2015 | 247 | 0.120 |
Why?
|
| Retinal Neurons | 1 | 2014 | 66 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 3772 | 0.110 |
Why?
|
| Arterioles | 2 | 2011 | 254 | 0.110 |
Why?
|
| Cell Communication | 3 | 2011 | 1621 | 0.110 |
Why?
|
| Glaucoma | 1 | 2022 | 1159 | 0.110 |
Why?
|
| Regeneration | 1 | 2001 | 1485 | 0.110 |
Why?
|
| Humans | 25 | 2023 | 744343 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2002 | 1363 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2021 | 4217 | 0.100 |
Why?
|
| Retrospective Studies | 9 | 2022 | 77449 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 6622 | 0.100 |
Why?
|
| Spermine | 1 | 2010 | 70 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 689 | 0.090 |
Why?
|
| Rats | 10 | 2011 | 24260 | 0.090 |
Why?
|
| Retinal Rod Photoreceptor Cells | 2 | 2001 | 195 | 0.090 |
Why?
|
| Electric Stimulation | 2 | 2006 | 1767 | 0.090 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 1209 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 2015 | 683 | 0.080 |
Why?
|
| Calcium | 4 | 2010 | 5756 | 0.080 |
Why?
|
| Dark Adaptation | 1 | 2009 | 219 | 0.080 |
Why?
|
| Calcium Channels, L-Type | 1 | 2010 | 240 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2019 | 2948 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 9734 | 0.080 |
Why?
|
| Fura-2 | 2 | 2010 | 109 | 0.080 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 391 | 0.080 |
Why?
|
| Ion Channels | 3 | 2003 | 1056 | 0.080 |
Why?
|
| Refractive Errors | 1 | 2009 | 142 | 0.080 |
Why?
|
| Stem Cells | 1 | 2001 | 3567 | 0.080 |
Why?
|
| Electroretinography | 1 | 2009 | 509 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2019 | 1901 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2021 | 5021 | 0.080 |
Why?
|
| Male | 17 | 2021 | 350118 | 0.070 |
Why?
|
| Chloride Channels | 2 | 2006 | 227 | 0.070 |
Why?
|
| Pinacidil | 1 | 2006 | 10 | 0.070 |
Why?
|
| Middle Aged | 11 | 2021 | 213383 | 0.070 |
Why?
|
| Animals | 15 | 2022 | 168757 | 0.070 |
Why?
|
| Biopsy | 1 | 2019 | 6756 | 0.070 |
Why?
|
| Vision, Ocular | 2 | 2019 | 464 | 0.070 |
Why?
|
| Medicaid | 1 | 2019 | 2736 | 0.070 |
Why?
|
| Intercellular Junctions | 1 | 2006 | 203 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 18029 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 5751 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2003 | 1504 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 2158 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 1116 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7181 | 0.060 |
Why?
|
| Exons | 1 | 2009 | 2437 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 39050 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1799 | 0.060 |
Why?
|
| Visual Fields | 1 | 2009 | 1047 | 0.050 |
Why?
|
| Age of Onset | 1 | 2009 | 3271 | 0.050 |
Why?
|
| Muscarinic Agonists | 1 | 2003 | 87 | 0.050 |
Why?
|
| Carbachol | 1 | 2003 | 226 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2003 | 8301 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2003 | 156 | 0.050 |
Why?
|
| Mice | 5 | 2022 | 81183 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5137 | 0.050 |
Why?
|
| Adult | 10 | 2021 | 214055 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2014 | 5097 | 0.050 |
Why?
|
| Gap Junctions | 1 | 2003 | 233 | 0.050 |
Why?
|
| Electrophysiology | 2 | 2001 | 1308 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2001 | 171 | 0.050 |
Why?
|
| Glyburide | 1 | 2001 | 113 | 0.050 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 322 | 0.050 |
Why?
|
| Night Blindness | 1 | 2001 | 53 | 0.050 |
Why?
|
| Acetylcholine | 1 | 2003 | 621 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 428 | 0.050 |
Why?
|
| Thigh | 1 | 2002 | 247 | 0.050 |
Why?
|
| Muscle Contraction | 2 | 2003 | 1240 | 0.050 |
Why?
|
| Cyclic GMP | 1 | 2001 | 409 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2001 | 114 | 0.050 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2001 | 291 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2022 | 15295 | 0.040 |
Why?
|
| Benzazepines | 1 | 2001 | 326 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2021 | 53288 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2001 | 491 | 0.040 |
Why?
|
| Sclera | 1 | 2020 | 200 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2020 | 473 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 2003 | 647 | 0.040 |
Why?
|
| Chlorides | 1 | 2001 | 667 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 13695 | 0.040 |
Why?
|
| Photoreceptor Cells | 1 | 2019 | 244 | 0.040 |
Why?
|
| Electric Conductivity | 2 | 2011 | 411 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 2022 | 642 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 1950 | 0.040 |
Why?
|
| Microvessels | 1 | 2021 | 544 | 0.040 |
Why?
|
| Child | 2 | 2017 | 77709 | 0.030 |
Why?
|
| Female | 11 | 2021 | 380194 | 0.030 |
Why?
|
| Transgenes | 1 | 2019 | 1009 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 1917 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2020 | 63114 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2022 | 1387 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1999 | 1124 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2001 | 1072 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2020 | 1270 | 0.030 |
Why?
|
| Cornea | 1 | 2022 | 1524 | 0.030 |
Why?
|
| Adolescent | 4 | 2019 | 85781 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 4456 | 0.030 |
Why?
|
| Cell Division | 1 | 2001 | 4568 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2019 | 1224 | 0.030 |
Why?
|
| Microglia | 1 | 2001 | 1266 | 0.030 |
Why?
|
| Disease Progression | 1 | 2009 | 13284 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2001 | 2132 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 56430 | 0.030 |
Why?
|
| Aged | 6 | 2020 | 163280 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2006 | 23403 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2015 | 1588 | 0.020 |
Why?
|
| Vasoconstriction | 2 | 2004 | 597 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 57776 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2011 | 152 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 25043 | 0.020 |
Why?
|
| Models, Biological | 1 | 2006 | 9583 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2019 | 3420 | 0.020 |
Why?
|
| Calcium Channels | 2 | 2004 | 622 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8642 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 35136 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 5867 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 1525 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 41006 | 0.020 |
Why?
|
| Sex Factors | 1 | 2020 | 10397 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 6171 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 19905 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3336 | 0.020 |
Why?
|
| Benzophenanthridines | 1 | 2004 | 27 | 0.020 |
Why?
|
| Phenanthridines | 1 | 2004 | 51 | 0.020 |
Why?
|
| Time Factors | 2 | 2021 | 40075 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 21827 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2001 | 11483 | 0.010 |
Why?
|
| Uridine Triphosphate | 1 | 2003 | 26 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 12072 | 0.010 |
Why?
|
| Alkaloids | 1 | 2004 | 190 | 0.010 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2003 | 85 | 0.010 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2003 | 153 | 0.010 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 76 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2001 | 275 | 0.010 |
Why?
|
| Methylene Blue | 1 | 2001 | 155 | 0.010 |
Why?
|
| Nifedipine | 1 | 2001 | 226 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 21746 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 20947 | 0.010 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2003 | 494 | 0.010 |
Why?
|
| Tetraethylammonium | 1 | 1999 | 58 | 0.010 |
Why?
|
| Rhodopsin | 1 | 2001 | 203 | 0.010 |
Why?
|
| Microdialysis | 1 | 1999 | 158 | 0.010 |
Why?
|
| Blood-Retinal Barrier | 1 | 1999 | 62 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 1227 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1999 | 437 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 13102 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2001 | 977 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 11725 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 6256 | 0.010 |
Why?
|
| Light | 1 | 2001 | 1374 | 0.010 |
Why?
|
| United States | 1 | 2019 | 69872 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 3798 | 0.010 |
Why?
|